In addition to direct antitumour mechanisms, IFN-α2b was shown to eliminate CML cells by activating circulating PR1-specific CTLs, a subtype of T cells involved in cytogenetic remission and usually deleted in untreated CML [185]. The gene discussed is TMEM37; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.